Intra-Cellular Therapies Valuation
Is ITCI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ITCI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ITCI * (MX$1529.77) is trading below our estimate of fair value (MX$7188.91)
Significantly Below Fair Value: ITCI * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ITCI *?
Key metric: As ITCI * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ITCI *'s PS Ratio? | |
|---|---|
| PS Ratio | 14.7x |
| Sales | US$613.73m |
| Market Cap | US$9.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 13.2x |
| Enterprise Value/EBITDA | -66.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ITCI *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.3x | ||
LAB B Genomma Lab Internacional. de | 1.4x | 9.9% | Mex$24.9b |
688506 Sichuan Biokin PharmaceuticalLtd | 13.8x | -36.8% | CN¥80.8b |
000999 China Resources Sanjiu Medical & Pharmaceutical | 2.3x | 9.8% | CN¥58.6b |
688578 Shanghai Allist Pharmaceuticals | 7.6x | 17.0% | CN¥24.5b |
ITCI * Intra-Cellular Therapies | 14.7x | 33.5% | Mex$9.1b |
Price-To-Sales vs Peers: ITCI * is expensive based on its Price-To-Sales Ratio (14.7x) compared to the peer average (6.3x).
Price to Sales Ratio vs Industry
How does ITCI *'s PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 189 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 189 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ITCI * is expensive based on its Price-To-Sales Ratio (14.7x) compared to the Global Pharmaceuticals industry average (2.6x).
Price to Sales Ratio vs Fair Ratio
What is ITCI *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 14.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ITCI *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Zai Lab
US$2.6b
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
ZLAB N
US$611.50
7D
0%
1Y
n/a